BRAF and melanoma: Finally, the anti-PD-L1 atezolizumab was recently approved by FDA for BRAF V600 mutated, advanced melanoma in combination with the BRAF and the mitogen-activated protein kinase (MEK) inhibitors vemurafenib and cobimetinib, respectively (see also Table 1).